Medtronic Expands Class I Recall of Insulin Pumps
October 5, 2021First New Treatment in a Decade for ANCA-Vasculitis Approved
October 8, 2021October 5, 2021 – Tecartus® (brexucabtagene autoleucel) has received a new indication to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults.
- First FDA-approved in 2020, Tecartus is a CAR-T therapy made from the patient’s own immune cells. It is also indicated to treat adults who have relapsed or refractory mantle cell lymphoma.
- Recommended dosing is based on individual patient factors such as diagnosis and body weight.
- Manufactured by Kite Pharma, Tecartus must be administered by a qualified healthcare professional in a certified medical facility.